Perrigo has entered an agreement to acquire a portfolio of GlaxoSmithKline’s OTC products in an undisclosed, all-cash transaction. The transaction is in connection with GSK’s commitments to the European Commission and other regulators to divest these businesses in the context of forming a consumer health joint venture between GSK and Novartis.   The portfolio includes well-established European brands in the areas of nicotine replacement therapy, cold and flu, and cold sore management. Sa...